Proposal to include Part B drug charges under MIPS scoring elicits concerns
Providers who routinely administer expensive prescription drugs that are billable to Medicare should keep a close eye on the pending Quality Payment Program (QPP) final rule — your future revenue may shrink or rise more dramatically than previously anticipated.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.